FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hans-Peter Hartung

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Ludwig Kappos; David Bates; Michel Clanet; David B Clifford; Gilles Edan; Mefkûre Eraksoy; Antonio Garcia-Merino; Ralf Gold; Nikolaos Grigoriadis; Hans-Peter Hartung; Stephen Hauser; Eva Havrdová; Jan Hillert; Hans H Hirsch; Reinhard Hohlfeld; Marcelo Kremenchutzky; Olivier Lyon-Caen; Eugene O Major; Ariel Miller; Paul W O'Connor; Carlo Pozzilli; Ernst W Radü; Mads Ravnborg; Takahiko Saida; Christian Sindic; Per Soelberg Sørensen; Karl Vass; Howard L Weiner; John King
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Chris H Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Joep Killestein; Henry McFarland; Joel Oger; Andrew R Pachner; John Petkau; Anthony T Reder; Stephen C Reingold; Huub Schellekens; Per Soelberg Sørensen
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Bastiaan Moraal; Christoph Pohl; Bernard M J Uitdehaag; Chris H Polman; Gilles Edan; Mark S Freedman; Hans-Peter Hartung; Ludwig Kappos; David H Miller; Xavier Montalban; Vivian Lanius; Rupert Sandbrink; Frederik Barkhof
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hans-Peter Hartung (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Ludwig Kappos; David Bates; Michel Clanet; David B Clifford; Gilles Edan; Mefkûre Eraksoy; Antonio Garcia-Merino; Ralf Gold; Nikolaos Grigoriadis; Hans-Peter Hartung; Stephen Hauser; Eva Havrdová; Jan Hillert; Hans H Hirsch; Reinhard Hohlfeld; Marcelo Kremenchutzky; Olivier Lyon-Caen; Eugene O Major; Ariel Miller; Paul W O'Connor; Carlo Pozzilli; Ernst W Radü; Mads Ravnborg; Takahiko Saida; Christian Sindic; Per Soelberg Sørensen; Karl Vass; Howard L Weiner; John King
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Lancet neurology 2011;10(8):745-58.
2010: Chris H Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Joep Killestein; Henry McFarland; Joel Oger; Andrew R Pachner; John Petkau; Anthony T Reder; Stephen C Reingold; Huub Schellekens; Per Soelberg Sørensen
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Lancet neurology 2010;9(7):740-50.
2009: Bastiaan Moraal; Christoph Pohl; Bernard M J Uitdehaag; Chris H Polman; Gilles Edan; Mark S Freedman; Hans-Peter Hartung; Ludwig Kappos; David H Miller; Xavier Montalban; Vivian Lanius; Rupert Sandbrink; Frederik Barkhof
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
Archives of neurology 2009;66(11):1345-52.
2009: Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederik Barkhof; Ernst W Radü; Carola Metzig; Lars Bauer; Vivian Lanius; Rupert Sandbrink; Christoph Pohl
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Lancet neurology 2009;8(11):987-97.
2009: Paul O'Connor; Massimo Filippi; Barry Arnason; Giancarlo Comi; Stuart Cook; Douglas Goodin; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Francis Boateng; Vitali Filippov; Maria Groth; Volker Knappertz; Christian Kraus; Rupert Sandbrink; Christoph Pohl; Timon Bogumil; P O'Connor; M Filippi; B Arnason; S Cook; D Goodin; H-P Harung; Ludwig Kappos; D Jeffery; H-P Hartung; G Comi
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
Lancet neurology 2009;8(10):889-97.
2008: Joep Killestein; Hans-Peter Hartung
Interferon beta in multiple sclerosis: predicting response at an early stage.
Journal of neurology, neurosurgery, and psychiatry 2008;79(6):616-7.
2008: Chris Polman; Ludwig Kappos; Mark S Freedman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederick Barkhof; Krzysztof Selmaj; Bernard Uitdehaag; Susanne Dahms; Lars Bauer; Christoph Pohl; Rupert Sandbrink
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.
Journal of neurology 2008;255(4):480-7.
2007: Frederik Barkhof; Chris H Polman; Ernst-Wilhelm Radue; Ludwig Kappos; Mark S Freedman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Peter A Poppe; Marlieke de Vos; Fatiha Lasri; Lars Bauer; Susanne Dahms; Klaus Wagner; Christoph Pohl; Rupert Sandbrink
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Archives of neurology 2007;64(9):1292-8.
2007: Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederik Barkhof; Ernst W Radü; Lars Bauer; Susanne Dahms; Vivian Lanius; Christoph Pohl; Rupert Sandbrink
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Lancet 2007;370(9585):389-97.
2007: Jessica M Nielsen; B Moraal; Chris H Polman; Peter A Poppe; M de Vos; Mark S Freedman; Ludwig Kappos; Frederik Barkhof; Lars Bauer; Christoph Pohl; Rupert Sandbrink; Hans-Peter Hartung; Bernard Uitdehaag
Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results.
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(6):717-21.
2007: Jens Kuhle; Christoph Pohl; Matthias Mehling; Gilles Edan; Mark S Freedman; Hans-Peter Hartung; Chris H Polman; David H Miller; Xavier Montalban; Frederik Barkhof; Lars Bauer; Susanne Dahms; Raija L P Lindberg; Ludwig Kappos; Rupert Sandbrink
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
The New England journal of medicine 2007;356(4):371-8.
2005: Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry Wolinsky
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Annals of neurology 2005;58(6):840-6.
2003: Frederik Barkhof; Mara Rocca; Gordon Francis; Jan-Hein T M van Waesberghe; Bernard Uitdehaag; Otto R Hommes; Hans-Peter Hartung; Luca Durelli; Gilles Edan; Oscar Fernández; Pierette Seeldrayers; Per Sørensen; Simon Margrie; Marco Rovaris; Giancarlo Comi; Massimo Filippi
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
Annals of neurology 2003;53(6):718-24.
2001: W I McDonald; Alastair Compston; Gilles Edan; Donald Goodkin; Hans-Peter Hartung; Fred D Lublin; Henry McFarland; D W Paty; Chris H Polman; Stephen C Reingold; Magnhild Sandberg-Wollheim; William A Sibley; A Thompson; S van Den Noort; B Y Weinshenker; Jerry Wolinsky
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
Annals of neurology 2001;50(1):121-7.